These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 171306)

  • 21. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
    Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
    Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of the toxicity of the pertussis component of the Di-Te-Per vaccine].
    Gołobów M; Kardymowicz B; Kudelski Z; Rymkiewicz D; Sawicki J
    Med Dosw Mikrobiol; 1986; 38(1):9-14. PubMed ID: 2423821
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals.
    Sato Y; Sato H
    Dev Biol Stand; 1991; 73():251-62. PubMed ID: 1778317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
    Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
    Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pertussis. Critical revision of its physiopathology. Implications].
    Fiore D
    Pediatr Med Chir; 1996; 18(1):109-12. PubMed ID: 8685015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of formaldehyde on the toxicity and potency of pertussis vaccine.
    Gottshall RY; Nelson E; Angela F; Anderson G
    Health Lab Sci; 1975 Jan; 12(1):35-40. PubMed ID: 1053237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of quantitative gene expression analysis for pertussis vaccine safety control.
    Hamaguchi I; Imai J; Momose H; Kawamura M; Mizukami T; Naito S; Maeyama J; Masumi A; Kuramitsu M; Takizawa K; Kato H; Mizutani T; Horiuchi Y; Nomura N; Watanabe S; Yamaguchi K
    Vaccine; 2008 Aug; 26(36):4686-96. PubMed ID: 18619509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
    Peppoloni S; Pizza M; De Magistris MT; Bartoloni A; Rappuoli R
    Physiol Chem Phys Med NMR; 1995; 27(4):355-61. PubMed ID: 8768791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
    Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
    Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of bacterial and synthetic peptidoglycans on the toxicity of a cell-free pertussis preparation].
    Zakharova NS; Shepeleva IB; Britsina MV; Ozeretskovskaia MN; Bazhanova IG
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Jan; (1):58-63. PubMed ID: 2330781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vaccine from cellular fragments of B. pertussis. II. Toxic properties of the vaccine].
    Shirko GN; Zakharova MS
    Zh Mikrobiol Epidemiol Immunobiol; 1978 Jul; (7):68-74. PubMed ID: 211762
    [No Abstract]   [Full Text] [Related]  

  • 33. The detoxification of Bordetella pertussis with glutaraldehyde.
    Iida T; Horiuchi Y
    J Biol Stand; 1987 Jan; 15(1):17-26. PubMed ID: 2881932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The safety and protective properties of a new cell-free pertussis vaccine in animal trials].
    Bazhanova IG; Remova TN; Ozeretskovskaia MN; Shmeleva EI; Mertsalova NU; Sukhinova EE; Chuprinina RP; Bulk VF; Semina IE; Koval'skaia SIa
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (1):40-5. PubMed ID: 8184612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On a possible new kind of toxic substance produced by Bordetella pertussis.
    Kurokawa M; Iwasa S; Ishida S
    Jpn J Med Sci Biol; 1965 Jun; 18(3):161-5. PubMed ID: 5294929
    [No Abstract]   [Full Text] [Related]  

  • 36. [Immunogenicity and toxicity of soluble trichloroacetic acid precipitate from pertussis microbes and its fractions].
    Bazhanova IG; Gladkaia VI; Liashenko VA
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Nov; (11):128-32. PubMed ID: 202117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolation from Bordetella pertussis of protective antigen free from toxic activity and histamine sensitizing factor.
    Nagel J
    Nature; 1967 Apr; 214(5083):96-7. PubMed ID: 4291816
    [No Abstract]   [Full Text] [Related]  

  • 38. Attempts at analysis of toxicity of pertussis vaccine. II. Quantitative determination of the heat-labile toxin by skin reaction.
    Kurokawa M; Ishida S; Asakawa S
    Jpn J Med Sci Biol; 1969 Oct; 22(5):293-307. PubMed ID: 4312799
    [No Abstract]   [Full Text] [Related]  

  • 39. [A study of toxic substances in pertussis cultures].
    Malivanova OM
    Zh Mikrobiol Epidemiol Immunobiol; 1976 Nov; (11):93-7. PubMed ID: 188276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [My involvement with pertussis vaccines--toxicity of pertussis vaccines and their toxicity tests].
    Kurokawa M
    Nihon Saikingaku Zasshi; 1983 May; 38(3):631-6. PubMed ID: 6655874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.